These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32501559)

  • 1. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
    Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study.
    Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
    Prostate; 2020 Apr; 80(5):432-440. PubMed ID: 32017175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
    Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
    Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
    Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
    Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer.
    Reverberi C; Massaro M; Osti MF; Anzellini D; Marinelli L; Montalto A; De Sanctis V; Valeriani M
    Sci Rep; 2020 Oct; 10(1):17471. PubMed ID: 33060732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
    Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
    Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.
    Gandaglia G; Fossati N; Stabile A; Bandini M; Rigatti P; Montorsi F; Briganti A
    Eur Urol; 2017 Aug; 72(2):289-292. PubMed ID: 27574820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
    Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
    Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
    Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
    Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
    BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
    Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P
    Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Si S; Zheng B; Wang Z; Niu Z
    Prostate; 2021 Aug; 81(11):736-744. PubMed ID: 34056739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and prognostic factors for patients with bone metastases from prostate cancer.
    He J; Zeng ZC; Yang P; Chen B; Jiang W; Du SS
    Asian J Androl; 2012 May; 14(3):505-8. PubMed ID: 22504872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
    Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
    Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
    Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
    Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
    Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
    Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    Ali A; Hoyle A; Mistry H; Clarke NW
    BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.